13F-HR filed by ARCH Venture Management, LLC
ARCH Venture Management, LLC filed this 13F-HR for the quarter ended 2025-12-31, filed 2026-02-17, with 9 holding rows worth $651,681,142.
- Accession
- 0001012975-26-000153
- Filer
- CIK 1274403
- Filed
- 2026-02-17
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2025
A holdings report, 9 entries on the cover page, a total value of $651,681,142 stated on the cover page (in dollars after the unit check, H1), rows summing to $651,681,142 with VALUE read as dollars as filed, 13F file number 028-19358. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| MAZE THERAPEUTICS INC COM | 578784100 | Stock | 4,120,053 | $170,693,796 | dollars as filed | |
| BEAM THERAPEUTICS INC | 07373V105 | COM | 4,540,132 | $125,852,459 | dollars as filed | |
| RAPPORT THERAPEUTICS INC COM | 75383L102 | Stock | 3,728,738 | $113,129,911 | dollars as filed | |
| LYELL IMMUNOPHARMA INC COM NEW | 55083R203 | Stock | 2,759,072 | $84,924,236 | dollars as filed | |
| VIR BIOTECHNOLOGY INC | 92764N102 | COM | 12,916,663 | $77,887,478 | dollars as filed | |
| ERASCA INC COM | 29479A108 | Stock | 11,055,554 | $41,126,661 | dollars as filed | |
| GOSSAMER BIO INC COM | 38341P102 | Stock | 8,055,916 | $24,973,340 | dollars as filed | |
| 10X GENOMICS INC CL A COM | 88025U109 | Stock | 737,539 | $12,029,261 | dollars as filed | |
| Q32 BIO INC | 746964105 | Common Stock | 320,482 | $1,064,000 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001012975-26-000153 | this filing | 2026-02-17 | acceptance time not in the bulk data set |